-
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
•
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy Officer. Based in the United States, Michael will report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. This strategic move aims to enhance Harbour BioMed’s global influence and business expansion. Role…
-
Juvensis Therapeutics Secures RMB100 Million for Heart Gene Therapy Development
•
Shanghai-based Juvensis Therapeutics, a specialist in anti-aging therapies, reportedly raised upwards of RMB100 million (USD13.8 million) via a Pre-Series A financing round. Led by Growth FoF, the funding included contributions from Nanjing Jiangbei New Area Sci-tech Investment Group, Henry WU, and Shanghai Healthcare Capital, among others. The proceeds will be…
-
Sun Pharma to Acquire Checkpoint Therapeutics for USD355 Million, Focusing on Cancer Immunotherapy
•
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of US-headquartered Checkpoint Therapeutics (NASDAQ: CKPT) for USD4.1 per share, totaling USD355 million. As part of the deal, Checkpoint shareholders will receive a contingent value right (CVR) entitling them to up to USD0.70 per share, contingent…
-
Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies
•
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree. Company BackgroundFounded in 2021, NeuroThree focuses on…
-
Geneseeq and MGI Tech Form Global Partnership for Oncology Solutions
•
Geneseeq Technology Inc., a genetic cancer testing service provider operating in Canada and China, has entered into a global partnership with China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114). The collaboration leverages MGI’s DNBSEQ gene sequencing platform to conduct in-depth cooperation in clinical basic research, product regulatory filing…
-
Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy
•
China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed partner to advance the development of HAT001/HBM9013, a novel corticotropin releasing hormone (CRH) targeted therapy. The alliance aims to promote the drug’s development globally, excluding Greater China. Agreement DetailsUnder the agreement, the partner will hold…
-
Green Valley and Vazyme Team Up on Alzheimer’s Disease Initiatives
•
China-based Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and Vazyme Biotech Co., Ltd (SHA: 688105) have entered into a strategic partnership to collaborate on the screening, diagnosis, and early intervention of Alzheimer’s disease (AD). Collaboration GoalsThe partnership will leverage the strengths of both companies to: Strategic SynergiesBy combining their expertise, Green…
-
CARsgen Therapeutics and Zhuhai SB Xinchuang Invest in UCARsgen for Allogeneic CAR-T Therapies
•
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has entered into an agreement with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise (Limited Partnership) to jointly invest in its subsidiary UCARsgen Biotech Limited. UCARsgen focuses on developing allogeneic CAR-T cell therapies for hematologic malignancies. Deal Highlights
-
Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues jumped 294.79% year-on-year (YOY) to RMB360.4 million ($49.67 million). Net loss attributable to the parent company was RMB856.77 million ($118 million), down RMB250.94 million ($34.6 million) from 2023. Key Highlights
-
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to support research in B cell development. Agreement DetailsUnder the agreement, Dr. James Kobie of UAB will receive a non-exclusive license to develop fully human…
-
Beihai Biotech Licenses Beizary to Zydus Lifesciences for US Market
•
China-based Zhuhai Beihai Biotech Co., Ltd announced a licensing agreement with Zydus Lifesciences, granting the India-headquartered firm exclusive commercialization rights to Beizary, a modified version of docetaxel, in the United States. Deal TermsUnder the agreement, Beihai will handle manufacturing and supply of Beizary. The company will receive an upfront payment…
-
Pfizer Partners with Alloy Therapeutics to Develop New Antibody Platform
•
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a multi-year partnership with compatriot firm Alloy Therapeutics Inc. The alliance is designed to develop a new platform aimed at enhancing Pfizer’s ability to discover potent, specific, and effective antibodies against targets that are difficult to address with existing antibody discovery…
-
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
•
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused biopharma co-founded with Blackstone Life Sciences in 2019, in a deal valued at up to USD 3.1 billion. The transaction underscores Novartis’ commitment to expanding its pipeline in thrombosis and cardiovascular diseases. Acquisition TermsAnthos shareholders…
-
Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from the European Commission (EC) for its serplulimab, combined with carboplatin and etoposide, as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) under the trade name Hetronifly. This approval marks serplulimab…
-
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
•
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has reportedly secured close to RMB200 million (USD27.6 million) in a Series C + financing round. The funding was led by Galaxy Finance, CMG – SDIC Capital, Yangtze River Industry Group, and other investors. The proceeds…
-
China Medical System Partners with MabGeek for Innovative Drug MG-K10
•
China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek Biotechnology Co., Ltd., a fellow Chinese biotech firm, for the latter’s Category 1 drug MG-K10. This marks CMS’s second major licensing deal in less than a month. Financial details of the agreement were not disclosed.…
-
Simcere Licenses Fermion’s AI-Enabled Painkiller FZ002-037
•
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced a licensing agreement with compatriot firm Fermion, an artificial intelligence (AI) empowered small-molecule drug developer, relating to an investigational SSTR4-targeted painkiller candidate drug, FZ002-037. This strategic partnership aims to advance the development and commercialization of FZ002-037 in Greater China, including mainland…
-
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of its compatriot firm Intra-Cellular Therapies Inc. (NASDAQ: ITCI) for USD 132 per share in cash, amounting to a total transaction value of USD 14.6 billion. This strategic acquisition aims to bolster J&J’s presence in the…
-
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
•
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm Timberlyne Therapeutics, Inc., granting the startup biopharma exclusive development, manufacturing, and commercialization rights to its CM313, a CD38-targeted monoclonal antibody (mAb). The agreement covers global rights, excluding mainland China, Hong Kong, Macau, and Taiwan. Financial…
-
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
•
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C financing round, raising RMB 150 million (USD 20.5 million). The investment was led by Huajin Capital, Bayland Capital, Infinity Capital, and returning investor Hankang Capital. The funds will be used to enhance the clinical development…
